Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A single infusion of zola-cel, a CD19-directed CAR T-cell therapy, is showing early but striking results in patients with treatment-refractory multiple sclerosis. In the phase 1 BREAKFREE-2 study, all patients at the higher dose remained off disease-modifying therapies at last follow-up, with no new disease activity seen in relapsing MS patients and mostly stable disability in progressive MS. Larger studies are still needed to confirm durability and long-term safety.
A single infusion of zolacabtagene autoleucel (zola-cel), an investigational CD19-directed CAR T-cell therapy from Bristol Myers Squibb, is generating buzz in the MS world after interim data from the phase 1 BREAKFREE-2 study were presented at MSToronto 2026. The therapy works by achieving deep B-cell depletion — not just in the bloodstream but also within the central nervous system — essentially attempting an "immune reset" that could lead to long-lasting disease control without ongoing medication.
The results so far are encouraging. Among patients with highly active relapsing MS treated at the higher dose, all 4 evaluable patients achieved no evidence of disease activity (NEDA-3) at week 26. In progressive MS patients, 5 of 6 had no confirmed disability progression, and 1 even showed confirmed improvement. All patients at the higher dose remained off disease-modifying therapies at last follow-up — including 9 with more than 12 months of follow-up.
Key Takeaways:
Why it matters: MS patients who fail high-efficacy therapies have very limited options. If zola-cel's early signals hold up in larger, longer trials, it could represent a paradigm shift — offering a one-time treatment with the potential for durable, treatment-free remission in both relapsing and progressive MS.
